GI Dynamics and GlaxoSmithKline announced results from a study on EndoBarrier and increased postoperative levels of bile acids (BAs) in patients with severe obesity, with and without type 2 diabetes. The data was presented at Digestive Disease Week in Chicago, IL.

Previous research has suggested that increased postoperative levels of BAs could be connected to the effectiveness of the Roux-en-Y gastric bypass (RYGB). In evaluating EndoBarrier and BAs, 17 patients with severe obesity, without and without type 2 diabetes, were treated with the device and evaluated after 52 weeks. In addition to 16% total body weight loss, fasting total BAs levels were over twice as high compared to baseline levels (1.3±0.3 vs. 3±0.5μMol/L, P<0.05). After a standard test meal, nutrient-stimulated levels of total BAs went up by 70% (475 vs. 805 AU, P<0.05).

RELATED: Non-Surgical Device for Type 2 Diabetes and Weight Loss

EndoBarrier is a flexible device that constructs a physical barrier between a portion of the intestinal wall and consumed food to adjust hormone release that reduces appetite and controls blood sugar for up to one year. It has already been approved for use in Australia, Europe, and Chile. GI Dynamics is conducting clinical trials in 18 cities across the U.S. with EndoBarrier for the treatment of type 2 diabetes in patients who are also trying to lose weight.

For more information visit